description
Sanofi (NYSE: SNY) is one of the globe's biggest drug companies. It's a major player in diabetes treatments, vaccines, and consumer medicines and is often included in dividend portfolios. However, looming patent expiration on its top selling drug, falling margin, and potential competition from Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) could all impact Sanofi's bottomline and threaten Sanofi's dividend. In the following slideshow you'll learn whether I think Sanofi's dividend is safe and see how Sanofi's dividend matches up to Lilly and Novo Nordisk.